Executive summary: The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity
Background
The prevalence of overweight and obesity among people in England and Wales is increasing. Associated serious health consequences in adults include Type 2 diabetes, cardiovascular disease, musculoskeletal disorders, certain cancers and increased mortality. Childhood obesity is associated with a higher chance of premature death and disability in adulthood. Obesity imposes a considerable economic burden on society. Weight loss improves obesity-related comorbidities and may have a mortality benefit. The intensity of intervention depends on the degree of obesity and presence of comorbidities. Management begins in primary care, but moves to the specialist setting when initial measures have failed and surgery is being considered. Bariatric (weight loss) surgery is increasing, but is not uniformly available across the country and a significant proportion is funded privately.
Objectives
To assess the clinical effectiveness and costeffectiveness of bariatric surgery for obesity.
Methods

Data sources
Seventeen electronic resources, including MEDLINE, EMBASE and Cochrane, were searched from inception to August 2008. Bibliographies of related papers were assessed and experts were contacted to identify additional published and unpublished references.
Study selection
Titles and abstracts were screened for eligibility by two independent reviewers. Inclusion criteria were defined a priori and applied to the full text of retrieved papers by two independent reviewers using a standard form. The inclusion criteria were as follows:
• Intervention Open and laparoscopic bariatric surgical procedures in widespread current use.
• The study types that were eligible for inclusion were:
• Systematic review of clinical effectiveness Surgery versus surgery -randomised controlled trials (RCTs); surgery versus non-surgical procedure -RCTs, controlled clinical trials and prospective cohort studies (with a control cohort).
• Systematic review of cost-effectiveness Full costeffectiveness analyses, cost-utility analyses, cost-benefit analyses and cost-consequence analyses.
Data extraction and quality assessment
Data extraction was undertaken by one reviewer and checked by two reviewers. Two reviewers independently applied quality assessment criteria. Differences in opinion were resolved through discussion at each stage.
Data synthesis
Studies were synthesised through a narrative review with full tabulation of the results of all included studies.
Economic model
The analysis was developed for three patient populations covered by studies included in the clinical effectiveness review:
• patients with morbid obesity BMI ≥ 40 undergoing adjustable gastric banding (AGB) or gastric bypass (GBP) • patients with moderate-to-severe obesity (BMI ≥ 30 and < 40) with significant comorbidity at baseline (Type 2 diabetes) undergoing AGB • patients with moderate obesity (BMI ≥ 30 and < 35) undergoing AGB.
A model developed previously was used for patients with morbid obesity (BMI ≥ 40), with updated assumptions on costs, diabetes incidence, permanency of diabetes remission following surgery, and on the impact of BMI on health-state utility.
A new model, including cardiac heart disease and stroke was applied in the analysis of AGB for moderate-to-severely obese (BMI ≥ 30 and < 40) patients with Type 2 diabetes and for moderately obese (BMI ≥ 30 and < 35) patients. The analysis was initially undertaken for the period of the trial follow-up only, but also included extrapolations up to 20 years following surgery.
Results
Quantity and quality of studies
A total of 5386 references were identified. Twentysix studies (reported in 52 publications) were included in the review of clinical effectiveness. Three RCTs and three cohort studies compared surgery with non-surgical interventions; 20 RCTs compared different surgical procedures. Two studies focused on patients with a lower BMI (< 35 or < 40). The risk of bias of most of the trials was uncertain, only nine of the RCTs reported adequate sequence generation and only five reported adequate allocation concealment.
Summary of clinical effectiveness
Surgery versus non-surgical interventions
The evidence indicates that bariatric surgery is a more effective intervention for weight loss than non-surgical options. Surgery led to a greater reduction in weight in all six studies and the difference was statistically significant in five studies reporting a statistical comparison. In the two RCTs that reported outcomes at two years, mean per cent initial weight loss in the surgical groups was 20% and 21.6%, whereas the non-surgical groups had lost only 1.4% and 5.5% of their initial weight. In the two cohort studies reporting outcomes at two years, per cent weight change ranged from a weight loss of 16% to 28.6% in the surgical groups, but the non-surgical groups had gained weight with per cent weight change ranging from 0.1 to 0.5%. A large prospective cohort study [Swedish Obese Subjects (SOS) study] found that weight loss was still apparent 10 years following surgery, whereas patients receiving conventional treatment had gained weight. One RCT and one of two cohort studies assessing QoL found greater, and statistically significant, improvements after surgery on some measures, but not others. Two RCTs found that significantly fewer people had metabolic syndrome in the surgical group, and one found significantly higher remission of Type 2 diabetes following surgery. The SOS study found a statistically significant reduction in the incidence of three out of six comorbidities assessed at 10 years follow-up after surgery compared with conventional therapy.
Comparison of surgical procedures
Of the available surgical options assessed by RCTs there is evidence that GBP is more effective for weight loss than vertical banded gastroplasty (VBG) and AGB. Five of the seven included RCTs reported greater weight loss following GBP than VBG with per cent excess weight loss at one year ranging between 62.9% and 78.3% for GBP, and ranging between 43% and 62.9% for VBG. In two studies there was no statistically significant difference in 'success rate' or 'per cent ideal body weight'. One RCT found per cent excess weight loss of 66.6% was significantly greater up to five years following laparoscopic GBP than following laparoscopic AGB, which led to per cent excess weight loss of 47.5% (p < 0.001). Evidence from one RCT shows laparoscopic isolated sleeve gastrectomy to be more effective than AGB with greater excess weight loss up to three years (median per cent excess weight loss 66% versus 48%, p = 0.0025 Changes in comorbidities after surgery were assessed by five of the 20 RCTs. In general, comorbidities improved in all groups with no significant differences in improvements observed between different surgical interventions.
Adverse events
The extent of reporting of adverse events varied between studies; few were compared statistically and none were powered to do so. Fourteen RCTs reported no deaths. Where deaths were reported separately for each RCT trial arm, mortality ranged from 2% (1/51 patients receiving Open GBP within the first 30 postoperative days) to 10% (2/20 patients receiving Open GBP, one on the fourth postoperative day, one after 13 months). The large SOS study reported mortality of 0.25% in the surgical cohort (5/2010 patients within 90 days of surgery). Adverse events from conventional therapy included intolerance to medication, acute cholecystitis and gastrointestinal problems. Major adverse events following surgery, some necessitating reoperation, included anastomosis leakage, pneumonia, pulmonary embolism, band slippage and band erosion.
Summary of cost-effectiveness
All modelled economic evaluations assessed in this report found that bariatric surgery was cost-effective in comparison to non-surgical treatment although the variability in estimates of costs and outcomes is large. The results of the economic evaluation alongside a clinical trial were inconclusive. However, because of the numerous methodological shortcomings and some poorly justified modelling assumptions the reported results are unlikely to be reliable and generalisable estimates of the incremental cost-effectiveness of bariatric surgery in comparison to non-surgical treatment.
Summary of economic model
Surgical management with GBP or AGB of morbid obesity (BMI > 40) was more costly than nonsurgical management, but results in improved outcomes (in terms of QALYs) over the modelled 20-year time horizon. The incremental costeffectiveness ratios (ICERs) ranged between £2000 and £4000 per QALY gained. The results were generally robust to changes in assumptions in the deterministic sensitivity analysis, and in all cases the ICERs remained within the range conventionally regarded as cost-effective from an NHS decision-making perspective.
Surgical management (with AGB) of moderate to severe obesity (BMI ≥ 30 and < 40) in patients with Type 2 diabetes was more costly than nonsurgical management, but resulted in improved outcomes. The ICER reduced with a longer time horizon from £18,930 at two years to £1367 at 20 years. The results were generally robust to changes in assumptions in the deterministic sensitivity analysis. In the probabilistic sensitivity analysis the probability of surgical management being cost-effective (compared with non-surgical management) was 2.5% at a willingness-to-pay threshold of £20,000 per QALY and 50.6% at a willingness-to-pay threshold of £30,000 per QALY, for a two-year time horizon, and was 100% at both thresholds, for a 20-year time horizon.
Surgical management (with AGB) of moderate obesity (BMI ≥ 30 and < 35) was estimated to be more costly than non-surgical management, but resulted in improved outcomes, though the QALY gain at two years is small (0.08). The ICER reduced with a longer time horizon from £60,754 at two years to £12,763 at 20 years. There was considerable variability in results, in the deterministic sensitivity analysis, with ICERs above the range conventionally deemed acceptable in some scenarios even for longer time horizons. In the probabilistic sensitivity analysis the probability of surgical management being cost-effective (compared with an intensive medical programme) was 64% at a willingness-to-pay threshold of £20,000 per QALY and 98% at a willingness-to-pay threshold of £30,000 per QALY with a 20-year time horizon. In contrast, for a two-year time horizon, the probability of surgical management being costeffective was zero at both thresholds.
Conclusions
Bariatric surgery appears to be a clinically effective and cost-effective intervention for moderately to severely obese people compared with non-surgical interventions. Uncertainties remain and further research is required, including:
• good-quality, long-term RCTs and cohort studies to provide detailed data on:
• patient QoL to inform on the gains in utility associated with reduction in BMI • impact of surgeon experience on outcome of surgery • late complications leading to reoperation • more than one weight outcome measure with standard deviation about the mean reported to enable future meta-analysis • duration of remission of comorbidities and factors affecting this • resource use across the entire patient pathway to develop robust costings • good-quality RCTs to provide evidence on bariatric surgery for young people and for adults with class I or class II obesity. New research must report on the resolution and/or development of comorbidities such as Type 2 diabetes and hypertension so that the potential benefits of early intervention can be assessed.
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